Diverging Parkinson's Disease Pathology between GBAN370S ,LRRK2G2019S and engineered SNCAA53T iPSC-derived Dopaminergic Neurons
Ali FathiiD, Kiranmayee Bakshy, Lida Zieghami, Rebecca Fiene, Robert Bradley, Sarah Dickerson, Coby B. CarlsoniD, Scott J. Schachtele, Jing LiuiD
Abstract
Multiple neurodegenerative disorders, including Parkinsons disease (PD) and Alzheimers disease-associated dementia (ADAD), are linked with dopaminergic (DA) neuron death and a resulting reduction in dopamine levels in the brain. DA neuron degeneration and the risk of developing PD is connected to genetic mutations affiliated with lysosomal function and protein degradation. Accessible human cellular models for PD-relevant genetic mutations are needed to investigate mechanisms of DA cell death and define points of therapeutic intervention. Human induced pluripotent stem cell (iPSC)-derived midbrain DA neurons offer a developmentally and physiologically relevant in vitro model for investigating PD pathogenic mechanisms across genetic backgrounds. In this study, we generated DA neurons using iPSCs from two clinically diagnosed PD patients, one harboring an inherited GBAN370S mutation and the other a mutation in LRRK2G2019S and compared pathophysiology against DA neurons from genetically engineered SNCAA53T iPSCs and its isogenic apparently healthy normal (AHN) iPSCs. Our results present a novel phenotype for GBAN370S and LRRK2G2019S derived DA neurons, showing that they produced and released significantly more dopamine compared to the AHN and SNCAA53T mutant DA neurons. All mutant DA neurons developed deficient glucocerebrosidase (GCase) activity, increased mitochondrial stress, aberrant neuronal activity patterns, and increased -synuclein accumulation. Together these data suggest potentially divergent origins of PD pathogenesis in GBAN370S and LRRK2G2019S DA neurons. In addition, compound screening confirmed that GCase modulators can rescue enzyme activity and impact neural activity across all DA mutant neurons, to varying degrees. These data demonstrate unique in vitro phenotypes associated with PD and suggest a diversity of underlying mechanisms across different genetic backgrounds. Together, the cell lines used in this study present a valuable tool for new therapeutic discovery.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 2
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Dopamine and cortical iPSC-derived neurons with different Parkinsonian mutations show variation in lysosomal and mitochondrial dysfunction: implications for protein deposition versus selective cell loss
Jessica Chedid, Yan Li, … Nicolas L. Dzamko·npj Parkinson s DiseasePeer-reviewed·Jun 20, 2025
- Synaptic dysfunction and dysregulation of extracellular matrix-related genes in dopaminergic neurons derived from Parkinson's disease sporadic patients and with GBA1 mutations
Idan Rosh, Utkarsh Tripathi, … Shani Stern·bioRxiv·Apr 10, 2023
- GBA1 mutations alter neuronal firing and structure, regulating VGLUT2 and CRYAB in dopamine neurons
Eva Rodríguez‐Traver, Luz M. Suárez, … Carlos Vicario‐Abejón·bioRxiv·Aug 5, 2024
- Gene-corrected Parkinson's disease neurons show the A30P alpha-synuclein point mutation leads to reduced neuronal branching and function
Peter A. Barbuti, Bruno F. R. Santos, … Rejko Krüger·bioRxiv·Nov 5, 2020
- Comparative study of enriched dopaminergic neurons from siblings with Gaucher disease discordant for parkinsonism
Ellen Hertz, Gani Perez, … Yu Chen·Movement DisordersPeer-reviewed·Jun 26, 2025
- Reduced synaptic activity and dysregulated extracellular matrix pathways are common phenotypes in midbrain neurons derived from sporadic and mutation-associated Parkinson's disease patients
Shani Stern, Shong Lau, … Fred H. Gage·bioRxiv·Dec 31, 2021